Hjem › Urotelial (overgangscelle) karcinom › Oklahoma
Kliniske studier for Urotelial (overgangscelle) karcinom i Oklahoma
8 studier for Urotelial (overgangscelle) karcinom søker deltakere på steder i Oklahoma.
Byer i Oklahoma
Offisiell studietekst (engelsk)
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06524544Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT03866382A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- Urologic Specialists of Oklahoma, Tulsa
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06774131A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT04879329Circulating Tumor DNA Response In Urothelial Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. feb. 2026 · NCT07183319A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jan. 2026 · NCT06999187SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT05107674Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.